FindTrial
Sign In

Ertapenem 1000 MG

DRUG2 trials

Sponsors

Public Health Service of Amsterdam, Universidad del Norte

Conditions

CarbapenemClinical TrialDrug Resistance, BacterialEnterobacteriaceae InfectionsEscherichia Coli InfectionGonorrheaInfection Due to ESBL BacteriaKlebsiella Pneumoniae Infection

Phase 3

New AntiBiotic Treatment Options for Uncomplicated Anogenital GOnorrhoea
CompletedNCT03294395
Public Health Service of AmsterdamGonorrhea
Start: 2017-09-18End: 2020-06-05Updated: 2021-08-06

Phase 4

Piperacillin/Tazobactam Versus Carbapenems in Non-bacteremic UTI Due to -ESBL-producing Enterobacteriaceae
SuspendedNCT03891433
Universidad del NorteCarbapenem, Clinical Trial, Drug Resistance, Bacterial +5
Start: 2019-04-01End: 2026-04-01Target: 198Updated: 2024-12-06

Related Papers

Diarrhoea as a frequent adverse event after intramuscular ertapenem treatment for uncomplicated <i>Neisseria gonorrhoeae</i>: a secondary analysis from the NABOGO trial.
2026-01-16
Spontaneous clearance of asymptomatic anogenital and pharyngeal <i>Neisseria gonorrhoeae</i>: a secondary analysis from the NABOGO trial
Sexually Transmitted Infections2022-07-1210 citations
Efficacy of ertapenem, gentamicin, fosfomycin, and ceftriaxone for the treatment of anogenital gonorrhoea (NABOGO): a randomised, non-inferiority trial.
2022-01-1935 citations